BrightSpring Health Services, Inc. — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
BrightSpring reported Q2 2026 net revenue of $3,873M (up 23% YoY) and adjusted EBITDA of $206M (up 44% YoY), following completion of Community Living divestiture on March 30, 2026. The company raised full-year 2026 guidance to $15.1-15.4B revenue (17-19.5% growth) and $820-845M adjusted EBITDA (32.8-36.8% growth). Key actions: $300M debt paydown with First Lien Facility refinancing; $60M stock repurchase of 1,026,465 shares; leverage improved to 2.15x from 2.27x. Amedisys/LHC acquisition expected to contribute ~$35M adjusted EBITDA in 2026.
Why this rating
Strong operating leverage (EBITDA growth 2.6x revenue growth), debt reduction, and raised guidance support positive momentum. At ~$2.3B market cap, $206M quarterly EBITDA represents ~9% run-rate; divestiture refocus and ~$820M FY guidance materially meaningful. Not transformational (no mega-deal), but solid execution warrants moderate-to-significant rating.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.